Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.72 |
| ▸ | MAPT | P10636 | 15/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2389106 | 0.90 | MAPT (0.71) | HTR6MAPTALDH1A1GAAHTT | |
| SCHEMBL2483679 | 0.84 | HTR6 (1.00) | HTR6MAPTALDH1A1GAAHTT | |
| SCHEMBL1848333 | 0.82 | HTR6 (0.71) | HTR6MAPTALDH1A1HTTNPSR1 | |
| SCHEMBL2481118 | 0.82 | MAPT (1.00) | HTR6MAPTALDH1A1GAAHTT | |
| SCHEMBL2390186 | 0.82 | L3MBTL1 (0.67) | HTR6MAPTALDH1A1HTTNPSR1 | |
| SCHEMBL2393153 | 0.80 | MAPT (1.00) | HTR6MAPTALDH1A1GAAHTT | |
| SCHEMBL1846574 | 0.80 | MAPT (0.69) | HTR6MAPTALDH1A1HTTNPSR1 | |
| SCHEMBL2390279 | 0.80 | MEN1 (0.67) | HTR6MAPTALDH1A1HTTNPSR1 | |
| SCHEMBL2392013 | 0.80 | MAPT (0.71) | HTR6MAPTALDH1A1GAAHTT | |
| SCHEMBL2389087 | 0.79 | MAPT (0.68) | HTR6MAPTALDH1A1HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11568956-B2 | Methods for identifying inhibitors of amyloid protein aggregation | TREVENTIS CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-20190050526-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2019-02-14 | — | — | US | disclosed |
| US-20160283652-A1 | METHODS FOR IDENTIFYING INHIBITORS OF AMYLOID PROTEIN AGGREGATION | TREVENTIS CORPORATION (US) | 2016-09-29 | — | — | US | disclosed |
| US-8420640-B2 | Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine | TREVENTIS CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | TREVENTIS CORPORATION | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218200-A1 | METHODS OF TREATING AMYLOID DISEASE USING ANALOGS OF 1-(4-NITROPHENYL) PIPERAZINE | PSEN1, PSEN2, APP | HTR6 1377/4885MAPT 10/4885ALDH1A1 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.